Compare
Immunovant, Inc. vs Vir Biotechnology, Inc. vs Iovance Biotherapeutics, Inc. vs Immunocore Holdings plc
| Latest fiscal year | Immunovant, Inc. IMVT | Vir Biotechnology, Inc. VIR | Iovance Biotherapeutics, Inc. IOVA | Immunocore Holdings plc IMCR |
|---|---|---|---|---|
| Year ended | 2026-03-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $68.56M | $263.50M | $400.02M |
| Revenue growth (YoY) | n/a | -7.6% | +60.6% | +29.0% |
| Gross margin | n/a | n/a | 34.3% (computed) | n/a |
| Operating margin | n/a | -699.2% | -153.1% | -11.3% |
| Net margin | n/a | -638.9% | -148.4% | -8.9% |
| Net income | -$505.61M | -$437.99M | -$390.98M | -$35.51M |
| EPS (Diluted) | -$2.77 | -$3.16 | -$1.09 | -$0.71 |
| Operating cash flow | -$407.31M | -$391.78M | -$302.41M | -$10.71M |
| Free cash flow | -$407.32M | -$396.61M | -$336.24M | -$15.05M |
| Cash & equivalents | $902.11M | $232.19M | $163.08M | $467.71M |
| Total assets | $957.01M | $1.00B | $913.17M | $1.07B |
| Total liabilities | $104.42M | $237.55M | $214.59M | $686.24M |
| Shareholders' equity | $852.59M | $765.28M | $698.58M | $381.03M |
| Return on year-end equity | -59.3% | -57.2% | -56.0% | -9.3% |
| Shares outstanding | 203.94M | 139.47M | 411.94M | 50.69M |
Revenue, most recent five fiscal years
| Fiscal year | Immunovant, Inc. | Vir Biotechnology, Inc. | Iovance Biotherapeutics, Inc. | Immunocore Holdings plc |
|---|---|---|---|---|
| Latest | n/a | $68.56M Ended 2025-12-31 | $263.50M Ended 2025-12-31 | $400.02M Ended 2025-12-31 |
| 1 year earlier | n/a | $74.20M Ended 2024-12-31 | $164.07M Ended 2024-12-31 | $310.20M Ended 2024-12-31 |
| 2 years earlier | n/a | $86.18M Ended 2023-12-31 | $1.19M Ended 2023-12-31 | $249.43M Ended 2023-12-31 |
| 3 years earlier | n/a | $1.62B Ended 2022-12-31 | n/a | $174.36M Ended 2022-12-31 |
| 4 years earlier | n/a | $1.10B Ended 2021-12-31 | n/a | $36.48M Ended 2021-12-31 |